Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources

Drug Metabolism and Disposition

Volumn 26, Issue 6, 1998, Pages 572-575

  Rotzinger, Susan ^b   Fang, Jian ^b   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ANTIDEPRESSANT AGENT; CYP2C9ARG; CYP2C9CYS; CYP2CB; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; KETOCONAZOLE; TRAZODONE; UNCLASSIFIED DRUG;

ARTICLE; DEPRESSION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; HUMAN CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PIPERAZINES; SEROTONIN AGONISTS; TRAZODONE;

EID: 0031795570     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Aranow RB, Hudson JI, Harrison GP, Grady TA, Laage TA, Bell IR and Cole JO (1989) Elevated antidepressant levels after addition of fluoxetine. Am J Psychiatry 146:911-913.
2. Baiocchi BL, Frigerio A, Giannangeli M and Palazzo G (1974) Basic metabolites of trazodone in humans. Arzneimittelforschung 24:1699-1706.
3. Conn JP and Sanders-Bush E (1987) Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors. J Pharmacol Exp Ther 242:552-557.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR and Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Pharmacol 34:262-265.
5. Fabre LF (1990) Trazodone dosing regimen: Experience with single daily administration. J Clin Psychiatry 51:23-26.
6. Fiorella D, Rabin RA and Winter JC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacol 119:222-230.
7. Greenblatt DJ, von Moltke LL, Schmider JS, Harmatz JS and Shader RI (1996) Inhibition of human cytochrome P4503A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies. J Clin Pharmacol 36:792-798.
8. Guengerich FP (1996) In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 24:521-533.
9. Haria M, Fitton A and McTavish D (1994) Trazodone: A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4:331-355.
10. Harvey AT and Preskorn SH (1995) Interactions of serotonin reuptake inhibitors with tricyclic antidepressants (Letter). Arch Gen Psychiatry 52:783-784.
11. Ishida M, Otani K, Kaneko S, Ohkubo T, Osanai T, Yasui N, Mihara K, Higuchi H and Sugawara K (1995) Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 10:143-146.
12. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
13. Jacobsen FM (1990) Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: A pilot study. J Clin Psychiatry 51:298-302.
14. Kahn RS and Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 30:1139-1166.
15. Macs M, Westenberg H, Vandoolaeghe E, Demedts P, Wauters A, Neels H and Metzler HY (1997) Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol 17:358-364.
16. Melzacka M, Boksa J and Maj J (1979) 1-(m-Chlorophenyl)piperazine: A metabolite of trazodone isolated from rat urine. J Pharm Pharmacol 31:855-856.
17. Metz. A and Shader RI (1990) Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 5:191-194.
18. Monteleone P, Gnocchi G and Delrio G (1989) Plasma trazodone concentrations and clinical response in elderly depressed patients: A preliminary study. J Clin Psychopharmacol 9:284-287.
19. Nierenberg AA, Cole JO and Glass L (1992) Possible trazodone potentiation of fluoxetine: A case series. J Clin Psychiatry 53:83-85.
20. Nierenberg AA, Adler LA, Peslow E, Zornberg G and Rosenthal M (1994) Trazodone for antidepressant-associated insomnia. Am J Psychiatry 151:1069-1072.
21. Nilsen OG, Dale O and Husebo B (1993) Pharmacokinetics of trazodone during multiple dosing to psychiatric patients. Pharmacol Toxicol 72:286-289.
22. Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T and Sugawara K (1996) Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Ther Drug Monit 18:164-167.
23. Preskorn S (1996) Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors (Appendix). Professional Communications, Inc., Cado, OK.
24. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS and Shader RI (1996) Inhibition of cytochrome P450 by nefazodone in vitro: Studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41:339-343.
25. Vatassery GT, Holden LA, Hazel DK and Dysken MW (1997) Determination of trazodone and its metabolite, 1-m-chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC. Clin Biochem 30:149-153.
26. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
27. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS and Shader RI (1995) Metabolism of drugs by cytochrome P450 3A isoforms: Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 29(Suppl. 1):33-44.
28. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-489.
29. 14C]trazodone hydrochloride in rats. Xenobiotica 4:313-326.
30. Yamato C, Takahashi T, Fujita T, Kuriyama S and Hirose N (1974b) Studies on the metabolism of trazodone: II. Metabolic fate after intravenous administration and effects on liver microsomal drug-metabolizing enzymes in rats. Xenobiotica 4:765-777.
31. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, Mihara K, Kondo T, Sugawara K and Fukushima Y (1995) Inhibition of trazodone metabolisn by thioridazine in humans. Ther Drug Monit 17:333-335.